Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL

Nicola Gianotti; Laura Galli; Sara Racca; Stefania Salpietro; Francesca Cossarini; Vincenzo Spagnuolo; Beatrice Barda; Filippo Canducci; Massimo Clementi; Adriano Lazzarin; Antonella Castagna

doi:10.1093/jac/dkr422

Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL

Nicola Gianotti, Laura Galli, Sara Racca, Stefania Salpietro, Francesca Cossarini, Vincenzo Spagnuolo, Beatrice Barda, Filippo Canducci, Massimo Clementi, Adriano Lazzarin, Antonella Castagna

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article › peer-review

Abstract

Objectives: It is currently debated whether patients with residual viraemia are at higher risk of virological failure than those attaining 50 copies/mL after baseline, and the time to virological rebound was calculated using the Kaplan-Meier method. Results: There were 739 eligible patients; 446 (60.4%) had HIV RNA 3 per year versus +21.2 (22.5, 53.2)cells/mm³ per year; P1/40.036. Conclusions: Residual viraemia assessed by kPCR was not associated with virological rebound during 1 year of follow-up. However, the patients attaining

Original language	English
Pages (from-to)	213-217
Number of pages	5
Journal	Journal of Antimicrobial Chemotherapy
Volume	67
Issue number	1
DOIs	https://doi.org/10.1093/jac/dkr422
Publication status	Published - 2012

Keywords

Antiretroviral therapy
HIV-1 viral load
Immune recovery
kPCR
Virological failure

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)
Infectious Diseases
Medicine(all)

Access to Document

10.1093/jac/dkr422

Fingerprint Dive into the research topics of 'Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL'. Together they form a unique fingerprint.

Cite this

Gianotti, N., Galli, L., Racca, S., Salpietro, S., Cossarini, F., Spagnuolo, V., Barda, B., Canducci, F., Clementi, M., Lazzarin, A., & Castagna, A. (2012). Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL. Journal of Antimicrobial Chemotherapy, 67(1), 213-217. https://doi.org/10.1093/jac/dkr422

Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL. / Gianotti, Nicola ; Galli, Laura; Racca, Sara; Salpietro, Stefania; Cossarini, Francesca; Spagnuolo, Vincenzo; Barda, Beatrice; Canducci, Filippo; Clementi, Massimo; Lazzarin, Adriano; Castagna, Antonella.

In: Journal of Antimicrobial Chemotherapy, Vol. 67, No. 1, 2012, p. 213-217.

Research output: Contribution to journal › Article › peer-review

Gianotti, N , Galli, L, Racca, S, Salpietro, S, Cossarini, F, Spagnuolo, V, Barda, B, Canducci, F, Clementi, M, Lazzarin, A & Castagna, A 2012, 'Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL', Journal of Antimicrobial Chemotherapy, vol. 67, no. 1, pp. 213-217. https://doi.org/10.1093/jac/dkr422

Gianotti, Nicola ; Galli, Laura ; Racca, Sara ; Salpietro, Stefania ; Cossarini, Francesca ; Spagnuolo, Vincenzo ; Barda, Beatrice ; Canducci, Filippo ; Clementi, Massimo ; Lazzarin, Adriano ; Castagna, Antonella. / Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL. In: Journal of Antimicrobial Chemotherapy. 2012 ; Vol. 67, No. 1. pp. 213-217.

@article{f424d575e23d442f88e0fb33d8d78aea,

title = "Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL",

abstract = "Objectives: It is currently debated whether patients with residual viraemia are at higher risk of virological failure than those attaining 50 copies/mL after baseline, and the time to virological rebound was calculated using the Kaplan-Meier method. Results: There were 739 eligible patients; 446 (60.4%) had HIV RNA 3 per year versus +21.2 (22.5, 53.2)cells/mm3 per year; P1/40.036. Conclusions: Residual viraemia assessed by kPCR was not associated with virological rebound during 1 year of follow-up. However, the patients attaining ",

keywords = "Antiretroviral therapy, HIV-1 viral load, Immune recovery, kPCR, Virological failure",

author = "Nicola Gianotti and Laura Galli and Sara Racca and Stefania Salpietro and Francesca Cossarini and Vincenzo Spagnuolo and Beatrice Barda and Filippo Canducci and Massimo Clementi and Adriano Lazzarin and Antonella Castagna",

year = "2012",

doi = "10.1093/jac/dkr422",

language = "English",

volume = "67",

pages = "213--217",

journal = "Journal of Antimicrobial Chemotherapy",

issn = "0305-7453",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL

AU - Gianotti, Nicola

AU - Galli, Laura

AU - Racca, Sara

AU - Salpietro, Stefania

AU - Cossarini, Francesca

AU - Spagnuolo, Vincenzo

AU - Barda, Beatrice

AU - Canducci, Filippo

AU - Clementi, Massimo

AU - Lazzarin, Adriano

AU - Castagna, Antonella

PY - 2012

Y1 - 2012

N2 - Objectives: It is currently debated whether patients with residual viraemia are at higher risk of virological failure than those attaining 50 copies/mL after baseline, and the time to virological rebound was calculated using the Kaplan-Meier method. Results: There were 739 eligible patients; 446 (60.4%) had HIV RNA 3 per year versus +21.2 (22.5, 53.2)cells/mm3 per year; P1/40.036. Conclusions: Residual viraemia assessed by kPCR was not associated with virological rebound during 1 year of follow-up. However, the patients attaining

AB - Objectives: It is currently debated whether patients with residual viraemia are at higher risk of virological failure than those attaining 50 copies/mL after baseline, and the time to virological rebound was calculated using the Kaplan-Meier method. Results: There were 739 eligible patients; 446 (60.4%) had HIV RNA 3 per year versus +21.2 (22.5, 53.2)cells/mm3 per year; P1/40.036. Conclusions: Residual viraemia assessed by kPCR was not associated with virological rebound during 1 year of follow-up. However, the patients attaining

KW - Antiretroviral therapy

KW - HIV-1 viral load

KW - Immune recovery

KW - kPCR

KW - Virological failure

UR - http://www.scopus.com/inward/record.url?scp=84859178656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859178656&partnerID=8YFLogxK

U2 - 10.1093/jac/dkr422

DO - 10.1093/jac/dkr422

M3 - Article

C2 - 21987242

AN - SCOPUS:84859178656

VL - 67

SP - 213

EP - 217

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 1

ER -